NVRO continues to gain due to its business expansion into the SI joint fusion market and optimistic 2024 results amid a weak SCS market.

minimized bone removal and increased fusion potential compared to a posterolateral cylindrical-threaded single-implant system. Expansion of SCS Systems Into the PDN Market: Nevro’s focus on ...

Globus Medical, Inc. GMED continues to benefit from the robust demand for its Musculoskeletal Solutions products. Following the NuVasive merger, the combined company has formed a global ...

The acquisition of Nevro is expected to expand Globus’ reach ... expanding its in-house production for NuVasive implants, consolidating external vendors and utilizing its existing product ...

Globus Medical GMED has experienced strong upward momentum in the past year, with its shares rising 41.8%. This has far outpaced the industry’s 7.5% decline and the S&P 500 composite’s 8.8% growth.

In 2022, the brain implants market was valued at over USD 5.7 billion, and its rapid expansion is fueled by several key factors. One of the most significant drivers is the rising incidence of nervous ...

Discover the top 3 undervalued Health Care Equipment & Supplies stocks for Wednesday, March 19 based on AAII’s Stock Grades.

Nevro has a 1-year low of $3.17 and a 1-year high of $14.70. Nevro ( NYSE:NVRO – Get Free Report ) last issued its quarterly earnings results on Tuesday, March 4th.